Volpara nets new FDA clearance

2020 03 10 18 26 4677 Volpara Rsna 2019 400

Breast imaging software developer Volpara Solutions has received U.S. Food and Drug Administration (FDA) clearance for version 3.2 of its Volpara Imaging Software (VIS).

Benefitting from artificial intelligence (AI), VIS 3.2 brings improvements to the company's breast density assessment algorithm, according to Volpara. In addition, VIS 3.2 also expands the use of the software to additional mammography systems from IMS Giotto and Siemens Healthineers, the company said.

What's more, the latest clearance includes Volpara's Open Virtual Appliance (OVA) architecture, which increases image processing security and enables Volpara to more easily monitor, service, and update software, the company said.

Page 1 of 156
Next Page